Skip to main content

Table 1 Demographic and disease characteristics by race at index visit

From: Longitudinal assessment of racial disparities in juvenile idiopathic arthritis disease activity in a treat-to-target intervention

 

White

Black

Asian/Other

 

N = 117

N = 21

N = 21

p-value*

Age, median (IQR)

11.6

13.0

10.6

0.20

(7.2–14.6)

(9.3–16.0)

(5.9–14.3)

 

Male sex, n (%)

14 (12%)

6 (29%)

7 (33%)

0.02

Hispanic ethnicity

3 (3%)

0 (0%)

4 (19%)

0.01

Public insurance

47 (40%)

15 (71%)

12 (57%)

0.02

Incident diagnosis (< 6 months)

37 (32%)

12 (57%)

9 (43%)

0.08

Rheumatoid factor positive

13 (11%)

11 (52%)

5 (24%)

< 0.01

Non-biologic DMARD use

61 (52%)

12 (57%)

13 (62%)

0.71

Biologic use

48 (41%)

6 (29%)

6 (29%)

0.43

cJADAS-10, median (IQR)

5.5

13.6

6.2

0.02

(0.5–13.6)

(9.5–19.0)

(0.7–17.0)

 

 Physician global assessment

1.0

4.0

1.5

< 0.01

(0.0–3.0)

(2.0–5.0)

(0.0–4.5)

 

 Patient/parent global assessment

2.0

4.4

2.8

0.06

(0.4–4.0)

(2.1–6.8)

(0.3–4.9)

 

 Joint count

0.0

5.0

1.0

0.06

(0.0–6.0)

(1.0–9.0)

(0.0–5.5)

 

Pain

1.9

6.3

3.2

0.01

(0.5–4.8)

(3.1–7.3)

(0.4–4.8)

 

PROMIS® upper extremity

49.0

31.8

47.0

0.05

(34.1–56.7)

(26.1–55.9)

(34.1–56.7)

 

PROMIS® mobility

48.0

35.0

48.0

0.02

(40.0–58.5)

(29.2–51.0)

(32.0–56.0)

 
  1. * Fisher’s exact test for categorical variables, Kruskal-Wallis test for continuous variables
  2. IQR interquartile range; DMARD disease-modifying anti-rheumatic drug; cJADAS-10 three-variable clinical Juvenile Arthritis Disease Activity Score; PROMIS® Patient Reported Outcomes Measurement Information System